mepa8 Get alerts

FDA approves Gazyva as first drug for adults with primary membranous nephropathy

In the Phase 3 MAJESTY trial, 36% of Gazyva patients reached complete remission of proteinuria at week 104, compared with 6% of patients given tacrolimus.

Mepa8 headline card: FDA approves Gazyva as first drug for adults with primary membranous nephropathy

Key takeaways

  • The FDA approved Gazyva (obinutuzumab) injection on Nov. 13, 2026, for adults with primary membranous nephropathy who are at risk of disease progression.
  • The agency calls it the first drug approved specifically for this rare kidney disease in adults.
  • In the 142-patient MAJESTY trial, 36% of patients on Gazyva reached complete remission of proteinuria at week 104, versus 6% of those on tacrolimus.
  • Gazyva carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (PML).
  • For crews: the FDA lists infusion-related reactions and upper respiratory tract infection as the most common side effects seen in the membranous nephropathy study.

The U.S. Food and Drug Administration has approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy who are at risk of disease progression, according to an FDA announcement dated Nov. 13, 2026. [1] The agency said the drug is approved to induce remission of proteinuria, the leakage of protein into the urine that marks the disease. [1]

The FDA described Gazyva as the "first drug approved specifically for the treatment of adults with primary membranous nephropathy." [1] The drug was already on the market for other uses, including certain cancers and other kidney conditions, according to the agency. [1]

The decision rests on MAJESTY, a Phase 3 trial that compared Gazyva with tacrolimus in 142 adults with the disease. At week 104, 36% of patients in the Gazyva group had reached complete remission, compared with 6% in the tacrolimus group, the FDA said. [1]

What the records show

The FDA describes primary membranous nephropathy as a rare kidney disease in which the immune system attacks the glomeruli, the small filtering units that clear waste from the blood. [1] According to the agency, the damaged and inflamed glomeruli let large amounts of protein escape into the urine. Patients can go on to develop high cholesterol, high blood pressure, severe swelling, fatigue and kidney failure, among other complications. [1]

MAJESTY (NCT04629248) was a randomized, controlled, open-label study run at multiple centers, the FDA said. [1] Over a main study period of 104 weeks, participants were randomly assigned to Gazyva or to tacrolimus. The agency noted that tacrolimus is a treatment "sometimes used off-label" for this disease. [1]

The primary endpoint was the share of patients in complete remission of proteinuria at week 104. [1] The FDA record defines complete remission as a urine protein-creatinine ratio (UPCR) of no more than 0.3 g/g together with a stable estimated glomerular filtration rate (eGFR). Patients counted toward that endpoint only if they had not needed rescue therapy, had not experienced treatment failure and had not left the study early. [1]

Trial arm (MAJESTY)Complete remission at week 104
Gazyva (obinutuzumab)36%
Tacrolimus6%

The agency said the remission rate was "significantly higher" in the Gazyva group. [1]

On safety, Gazyva's label includes a boxed warning for hepatitis B virus reactivation and for progressive multifocal leukoencephalopathy (PML). The FDA describes PML as a rare, serious brain infection caused by a virus in people whose immune systems are weakened. [1] In the membranous nephropathy study, infusion-related reactions and upper respiratory tract infection were the side effects reported most often, according to the agency. [1]

The FDA said Gazyva received Orphan Drug and Priority Review designations for this approval, along with an expedited-therapy designation listed in the announcement. [1]

Why it matters for clinicians

Until this approval, the FDA record indicates, no drug had been approved specifically for adults with primary membranous nephropathy. Tacrolimus, the comparator in MAJESTY, is described by the agency as an off-label option. [1] Nephrologists and other clinicians treating these patients now have a labeled therapy with Phase 3 data behind it.

The safety profile is relevant beyond the kidney clinic. The boxed warning covers hepatitis B virus reactivation and PML, a viral brain infection the FDA links to weakened immunity. [1] Infusion-related reactions were among the most common side effects in the trial. [1] Emergency, urgent care and prehospital clinicians may encounter patients on the drug, as well as patients with complications of the disease itself, which the FDA says include severe swelling, high blood pressure and kidney failure. [1] EMS clinicians follow local protocols and medical direction.

Context

Gazyva is not a new drug. The FDA said it had previously been approved to treat certain cancers, active lupus nephritis and childhood-onset idiopathic nephrotic syndrome. [1] The membranous nephropathy approval adds an adult kidney indication to that list.

What the records do not tell us

  • The FDA announcement does not give the dose, infusion schedule or duration of treatment; it refers readers to the full prescribing information, which is not part of these records. [1]
  • The announcement does not say how many of the 142 participants were assigned to each arm.
  • Rates of infusion reactions, infections or other adverse events are not reported, and the record does not say whether any cases of hepatitis B reactivation or PML occurred in the trial.
  • Results for partial remission, long-term kidney function or outcomes after week 104 are not described.
  • MAJESTY was open-label; the announcement does not discuss how that design may have affected the results.
  • The records do not name the manufacturer, and no company statement, price or launch timing appears in them.

Questions readers ask

What did the FDA approve for primary membranous nephropathy?

On Nov. 13, 2026, the FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria. The agency says it is the first drug approved specifically for this condition in adults.

How well did Gazyva work in the MAJESTY trial?

In the Phase 3 MAJESTY trial of 142 adults, 36% of patients on Gazyva achieved complete remission of proteinuria at week 104, compared with 6% of patients on tacrolimus, according to the FDA.

What are the main safety warnings for Gazyva?

Gazyva's label has a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (PML), a rare and serious viral brain infection. The most common side effects in the membranous nephropathy study were infusion-related reactions and upper respiratory tract infection.

What is primary membranous nephropathy?

The FDA describes it as a rare kidney disease in which the immune system attacks the glomeruli, the kidney's small filters, causing large amounts of protein to leak into the urine. Complications can include high cholesterol, high blood pressure, severe swelling, fatigue and kidney failure.

Sources

  1. FDA: FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy (Nov. 13, 2026) — fda.gov (2026-11-13). fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-ad
How this story was made Drafted by Mepa8's AI newsroom from the 1 record listed above and nothing else. Before publication a verification program confirmed that every number and quotation in the story appears in those records, that no passage was copied from them, and that every cited link opens. Editor: Ryan Bolden, EMS professional, who reviews published stories and handles corrections. Medical review pending. How we use AI · Report an error

This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.

Free alerts

Know about the next recall or outbreak the day it is posted.

One email when a story touches EMS equipment, medications or public health. Plus the free 6am briefing if you want it.

Send me